RxSight earnings release, August 5, 2026

RxSight, Inc. (RXST) · Form 8-K, Item 2.02 · Filed · SEC filing

RXSIGHT, INC. REPORTS SECOND QUARTER 2026 RESULTS AND PROVIDES UPDATE ON 2026 OUTLOOK

Aliso Viejo, Calif. – August 5, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financial outlook.

Second Quarter 2026 Highlights

• Total company Q2 revenue of $33.7 million, which includes $6.5 million in revenue recognized from the RxSight Alcon strategic collaboration

• Q2 product sales of $27.2 million including: o

24,917 Light Adjustable Lens (LAL) units; o

12 Light Delivery Devices (LDD) units

• Cash, cash equivalents and short-term investments of approximately $209 million as of June 30, 2026

Strategic Highlights

RxSight highlighted the following recent developments that position the company for long-term success:

• Appointed eye care industry leader Aziz Mottiwala as President and Chief Executive Officer

• Entered into a strategic collaboration with Alcon to develop and commercialize light-adjustable presbyopia-correcting intraocular lenses with up to $200 million upfront and milestone payments and significant future royalty potential

• Formally announced development of the next-generation RxSight Light Adjustable Technology platform, including new LAL, LAL+ and LAL Toric lenses intended to improve workflow and reduce required postoperative office visits

• In connection with the leadership transition, withdrew 2026 guidance; will resume formal guidance in early 2027

“It is a privilege to join RxSight and to work alongside the talented team that pioneered an entirely new category in cataract surgery with the only commercially available IOL platform that enables physicians to adjust and personalize vision after surgery,” said Aziz Mottiwala, President and Chief Executive Officer of RxSight. “The opportunity ahead is significant, and our immediate priority is to strengthen commercial execution, deepen adoption across our installed base and translate the value of adjustability into durable growth. To support those priorities, I have commenced a comprehensive review of the business. While underlying trends remain generally consistent with our prior expectations, withdrawing 2026 guidance gives us the flexibility to establish the right operating plan and focus our resources on the core business, our pipeline and the Alcon collaboration.”

Second Quarter Financial Results

In the second quarter of 2026, total revenue was $33.7 million, including $6.5 million recognized under the company’s strategic collaboration with Alcon. Product sales were $27.2 million, down 19% from the prior-year period, reflecting heightened competitive trialing and continued pressure on consumer sentiment.

Excluding the impact from the Alcon collaboration, second quarter gross margin of 71.2% decreased from 74.9% in the prior-year period, primarily reflecting inventory-related costs and the expected flow-through of higher-cost inventory. Including the favorable contribution of collaboration revenue, second-quarter gross margin was 76.7%.

Total operating expenses for the second quarter of 2026 were $39.7 million versus $39.2 million in the year-ago period. The increase was primarily driven by higher professional services fees, partially offset by lower compensation and other employee-related costs.

In the second quarter, the company reported a net loss of $(12.1) million, or $(0.29) per basic and diluted share, compared to a net loss of $(11.8) million, or $(0.29) per basic and diluted share in the second quarter of 2025. Adjusted net loss in the second quarter of 2026 was $(4.6) million, or $(0.11) per basic and diluted share, compared to an adjusted net loss of $(3.3) million, or $(0.08) per basic and diluted share in the second quarter of 2025.

As of June 30, 2026, cash, cash equivalents and short-term investments totaled $208.8 million.

Conference Call

On Wednesday, August 5, 2026, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its second quarter 2026 financial results. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 1245159. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL/LAL+, collectively the “LAL”), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Financial statements

Income Statement

Three Months Ended June 30, — (In thousands, except share and per share amounts)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue:Product sales27,24133,63758,13471,531
Revenue:License and collaboration revenue6,5006,500
Revenue:Total revenue33,74133,63764,63471,531
Costs and expenses:Cost of sales7,8558,44715,25018,013
Costs and expenses:Selling, general and administrative30,41928,97662,27457,611
Costs and expenses:Research and development9,23710,21718,70920,584
Costs and expenses:Total costs and expenses47,51147,64096,23396,208
Costs and expenses:Loss from operations-13,770-14,003-31,599-24,677
Other income (expense), net:Interest expense-3-5-6-11
Other income (expense), net:Interest and other income1,7642,2543,7184,762
Other income (expense), net:Loss before income taxes-12,009-11,754-27,887-19,926
Other income (expense), net:Income tax expense88329450
Other income (expense), net:Net loss-12,097-11,786-27,981-19,976
Other comprehensive loss:Unrealized loss on short-term investments-5-146-125-303
Other comprehensive loss:Foreign currency translation gain13141320
Other comprehensive loss:Total other comprehensive gain (loss)8-132-112-283
Other comprehensive loss:Comprehensive loss-12,089-11,918-28,093-20,259
Net loss per share:Basic & diluted-0.29-0.29-0.68-0.49
Weighted-average shares used in computing net loss per share:Attributable to common stock, basic & diluted41,490,88940,743,78641,399,01040,627,363

Income Statement

Three Months Ended June 30, — Reconciliation of gross margin and gross margin percentage to revenues and cost of sales for the three months ended June 30, 2026 and 2025 are as follows:

Three Months Ended June 30, – 2026 – ProductThree Months Ended June 30, – 2026 – CollaborationThree Months Ended June 30, – 2026 – TotalThree Months Ended June 30, – 2025 – ProductThree Months Ended June 30, – 2025 – CollaborationThree Months Ended June 30, – 2025 – Total
Sales27,2416,50033,74133,63733,637
Cost of sales7,8557,8558,4478,447
Gross profit19,3866,50025,88625,19025,190
Gross margin %71.2%100.0%76.774.9%0.0%74.9

Income Statement

Six Months Ended June 30, — Reconciliation of gross margin and gross margin percentage to revenues and cost of sales for the six months ended June 30, 2026 and 2025 are as follows:

Six Months Ended June 30, – 2026 – ProductSix Months Ended June 30, – 2026 – CollaborationSix Months Ended June 30, – 2026 – TotalSix Months Ended June 30, – 2025 – ProductSix Months Ended June 30, – 2025 – CollaborationSix Months Ended June 30, – 2025 – Total
Sales58,1346,50064,63471,53171,531
Cost of sales15,25015,25018,01318,013
Gross profit42,8846,50049,38453,51853,518
Gross margin %73.8%100.0%76.474.8%0.0%74.8

Income Statement

Three months ended June 30,

Three months ended June 30, – 2026Three months ended June 30, – 2025Six months ended June 30, – 2026Six months ended June 30, – 2025
Numerator:Net loss available to stockholders, basic and diluted-12,097-11,786-27,982-19,976
Add:Stock-based compensation7,4658,54715,41015,687
Add:Adjusted net earnings (loss) income available to common stockholders, basic and diluted:-4,632-3,239-12,572-4,288
Denominator:Weighted-average shares outstanding, basic41,490,88940,743,78641,399,01040,627,363
Denominator:Weighted-average shares outstanding, diluted41,490,88942,258,19341,399,01040,627,363
Denominator:Adjusted net earnings (loss) per share, basic-0.11-0.08-0.3-0.11
Denominator:Adjusted net earnings (loss) per share, diluted-0.11-0.08-0.3-0.11

Balance Sheet

December 31, — (In thousands, except share and per share amounts)

June 30, – 2026 – (Unaudited)December 31, – 2025
Current assets:Cash and cash equivalents13,35219,949
Current assets:Short-term investments195,447208,179
Current assets:Accounts receivable, net18,51923,383
Current assets:Inventories37,11731,559
Current assets:Prepaid and other current assets2,9614,389
Current assets:Receivable from collaboration partner60,000
Current assets:Total current assets327,396287,459
Current assets:Property and equipment, net14,03913,056
Current assets:Operating leases right-of-use assets9,4919,959
Current assets:Restricted cash750750
Current assets:Other assets1,024590
Current assets:Total assets352,700311,814
Current liabilities:Accounts payable6,3455,296
Current liabilities:Accrued expenses and other current liabilities15,55316,533
Current liabilities:Lease liabilities1,6641,162
Current liabilities:Deferred revenue, current6,8823,262
Current liabilities:Refund liability50,000
Current liabilities:Total current liabilities80,44426,253
Current liabilities:Long-term lease liabilities8,9169,878
Current liabilities:Total liabilities89,36036,131
Stockholders' equity:Common stock, $0.001 par value, 900,000,000 shares authorized, 41,585,381 shares issued and outstanding as of June 30, 2026 and 41,242,005 shares issued and outstanding as of December 31, 20254141
Stockholders' equity:Additional paid-in capital952,378936,628
Stockholders' equity:Accumulated other comprehensive (loss) income-5953
Full release

Forward-Looking Statements... (truncated) factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other similar terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risk factors that may be found in the section entitled Part II, Item 1A (Risk Factors) in the company’s Quarterly Report on Form 10-Q for the three months ended June 30, 2026, filed with the Securities and Exchange Commission (SEC) on or about the date hereof, and the other documents that RxSight may file from time to time with the SEC. These and other factors may cause our actual results to differ materially from any forward-looking statement. RxSight undertakes no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

RxSight, Inc., the RxSight Light Adjustable Lens Technology, LAL, LAL+, and LDD are trademarks of RxSight, Inc.

Investor Relations Contact:

Oliver Moravcevic

VP, Investor Relations omoravcevic@rxsight.com

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.